| Nov 11 |
Autonomix Medical reports Q2 results
|
| Nov 11 |
Autonomix Medical, Inc. Reports Second Quarter Fiscal Year 2025 Financial Results and Provides a Corporate Update
|
| Oct 31 |
Autonomix Medical, Inc. Reports New Positive Topline Results from First 15 Patients’ 7-Day Data Highlighting Significant Impact on Treatment of Pancreatic Cancer Pain with Maintained Pain Reduction
|
| Oct 30 |
Autonomix Medical, Inc.’s Dr. Robert Schwartz Discusses What Positive 4-6 Week Follow-Up Data Means from Lead-In Patients in Ongoing Human Clinical Trial
|
| Oct 28 |
Positive Preliminary Results Demonstrate Autonomix’s Proprietary RF Ablation Technology’s Ability to Reduce Opioid Use in Ongoing Human Clinical Trial
|
| Oct 25 |
Autonomix Medical, Inc. to Participate in a Virtual Investor “What This Means” Segment on Wednesday, October 30th
|
| Oct 22 |
Autonomix Medical to conduct a reverse stock split
|
| Oct 22 |
Autonomix Announces Reverse Stock Split
|
| Oct 8 |
Autonomix Medical, Inc. to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
|
| Sep 26 |
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Release of the Next CEO Corner Segment
|
